THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
THALES
A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack
2 other identifiers
interventional
11,016
28 countries
387
Brief Summary
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jan 2018
387 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2017
CompletedFirst Posted
Study publicly available on registry
November 28, 2017
CompletedStudy Start
First participant enrolled
January 22, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 13, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 13, 2019
CompletedResults Posted
Study results publicly available
December 22, 2020
CompletedDecember 22, 2020
December 1, 2020
1.9 years
November 20, 2017
November 18, 2020
December 21, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite of Subsequent Stroke or Death
Participants with subsequent stroke or death
From randomisation (day 1) to visit 3 (day 30-34)
Secondary Outcomes (2)
Ischaemic Stroke
From randomisation (day 1) to visit 3 (day 30-34)
Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3
Visit 3 (day 30-34)
Other Outcomes (4)
Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Severe
From randomisation (day 1) to visit 3 (day 30-34)
ICH or Fatal Bleeding Event
From randomisation (day 1) to visit 3 (day 30-34)
Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Moderate/Severe
From randomisation (day 1) to visit 3 (day 30-34)
- +1 more other outcomes
Study Arms (2)
TICAGRELOR
EXPERIMENTALTICAGRELOR PLACEBO
PLACEBO COMPARATORInterventions
Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Eligibility Criteria
You may qualify if:
- Provision of signed informed consent prior to any study-specific procedure
- ≥40 years of age
- Acute onset of cerebral ischaemia due to
- AIS with NIHSS ≤5. AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, and either of the following:
- Persistent signs or symptoms of the ischaemic event at the time o randomisation, OR
- Acute ischaemic brain lesion documented before randomisation by computed tomography (CT) scan or magnetic resonance imaging (MRI) (diffusion-weighted imaging) and that could account for the clinical presentation
- High-risk TIA, defined as neurological deficit of acute onset attributed to focal ischaemia of the brain by history or examination with complete resolution of the deficit, and at least one of the following:
- ABCD2 score ≥6 and TIA symptoms not limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo
- Symptomatic intracranial arterial occlusive disease that could account for the clinical presentation, documented by transcranial Doppler or vascular imaging and defined as at least 50% narrowing in the diameter of the vessel lumen
- Internal carotid arterial occlusive disease that could account for the clinical presentation, documented by Doppler, ultrasound, or vascular imaging and defined as at least 50% narrowing in diameter of the vessel lumen
- Randomisation occurring within 24 hours after onset of symptoms; for wake-up strokes (when the time of symptom onset is not known), within 24 hours from the time point at which the patient was reported to be in their normal condition
- CT or MRI performed after symptom onset ruling out intracranial haemorrhage or other pathology, such as vascular malformation, tumour, or abscess that according
- to the Investigator could explain symptoms or contraindicate study treatment
You may not qualify if:
- Need for or an anticipated need for any of the following:
- Dual antiplatelet therapy with ASA and P2Y12 inhibitors (including patients with carotid artery stenting and percutaneous coronary intervention)
- Antiplatelets other than ASA (eg, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol, ticagrelor) and other antithrombotic agents with antiplatelet effects, including traditional/herbal medicine agents
- Anticoagulants (eg, warfarin, oral thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, fondaparinux, or unfractionated heparin and long-term treatment with low-molecular weight heparins). Short-term treatment (≤7 days) with low-dose low-molecular weight heparin may be used in immobilised patients at the discretion of the Investigator
- Any history of atrial fibrillation/flutter, ventricular aneurysm, or suspicion of other cardioembolic pathology for TIA or stroke
- Patients who should receive or have received any intravenous or intra-arterial thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation
- History of previous intracranial haemorrhage at any time (asymptomatic microbleeds do not qualify), gastrointestinal haemorrhage within the past 6 months, or major surgery within 30 days
- Patients considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second- or third-degree atrioventricular block) unless already treated with a permanent pacemaker
- Inability of the patient to understand and/or comply with study procedures and/or follow-up, in the opinion of the Investigator
- Known hypersensitivity to ticagrelor or ASA
- Need for or an anticipated need for oral or intravenous therapy with any of the following:
- Strong cytochrome P450 3A (CYP3A4) inhibitors (eg, ketoconazole, clarithromycin \[but not erythromycin or azithromycin\], nefazadone, ritonavir, atazanavir) that cannot be stopped for the course of the study
- Long-term (\>7 days) non-steroidal anti-inflammatory drugs
- Known bleeding diathesis or coagulation disorder (eg, thrombotic thrombocytopenic purpura)
- Known severe liver disease (eg, ascites or signs of coagulopathy)
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (387)
Research Site
Adrogué, 1846, Argentina
Research Site
Buenos Aires, 1180AAX, Argentina
Research Site
Buenos Aires, 1437, Argentina
Research Site
Buenos Aires, AR-CP 1221, Argentina
Research Site
Buenos Aires, C1425 FSD, Argentina
Research Site
Buenos Aires, C1437BZK, Argentina
Research Site
Capital Federal, 1428, Argentina
Research Site
Ciudad Autónoma de Bs. As., C1199ABB, Argentina
Research Site
Córdoba, 5000, Argentina
Research Site
Mar del Plata, B7602CBM, Argentina
Research Site
Mendoza, M5500IDN, Argentina
Research Site
Rosario, S2000DSV, Argentina
Research Site
Rosario, S200GAP, Argentina
Research Site
Salta, A4400, Argentina
Research Site
Adelaide, 5000, Australia
Research Site
Heidelberg, 3084, Australia
Research Site
Herston, 4029, Australia
Research Site
Parkville, 3050, Australia
Research Site
Southport, 4215, Australia
Research Site
St Albans, 3021, Australia
Research Site
Antwerp, 2020, Belgium
Research Site
Assebroek (Brugge), 8310, Belgium
Research Site
Bruges, 8000, Belgium
Research Site
Brussels, 1200, Belgium
Research Site
Dendermonde, 9200, Belgium
Research Site
Edegem, 2650, Belgium
Research Site
Kortrijk, 8500, Belgium
Research Site
Leuven, 3000, Belgium
Research Site
Liège, 4000, Belgium
Research Site
Ostend, 8400, Belgium
Research Site
Roeselare, 8800, Belgium
Research Site
Sint-Truiden, 3800, Belgium
Research Site
Yvoir, 5530, Belgium
Research Site
Botucatu, 18618-687, Brazil
Research Site
Curitiba, 81210-310, Brazil
Research Site
Goiânia, 74083-100, Brazil
Research Site
Joinville, 89202-165, Brazil
Research Site
Maringá, 87015-000, Brazil
Research Site
Porto Alegre, 90610-000, Brazil
Research Site
Ribeirão Preto, 14015130, Brazil
Research Site
Rio de Janeiro, 22270-005, Brazil
Research Site
Salvador, 41820011, Brazil
Research Site
Dupnitsa, 2600, Bulgaria
Research Site
Kozloduy, 3320, Bulgaria
Research Site
Lukovit, 5770, Bulgaria
Research Site
Pazardzhik, 4400, Bulgaria
Research Site
Pleven, 5800, Bulgaria
Research Site
Sliven, 8800, Bulgaria
Research Site
Sofia, 1142, Bulgaria
Research Site
Sofia, 1407, Bulgaria
Research Site
Sofia, 1606, Bulgaria
Research Site
Teteven, 5700, Bulgaria
Research Site
Calgary, Alberta, T2N 2T9, Canada
Research Site
Edmonton, Alberta, T6G 2B7, Canada
Research Site
Lethbridge, Alberta, T1J 0N9, Canada
Research Site
Chicoutimi, G7H 5H6, Canada
Research Site
Baoji, 721008, China
Research Site
Baotou, 014016, China
Research Site
Beijing, 100049, China
Research Site
Beijing, 100070, China
Research Site
Beijing, 100191, China
Research Site
Changsha, 410013, China
Research Site
Changsha, 410078, China
Research Site
Changsha, 430033, China
Research Site
Chifeng, 024000, China
Research Site
Daqing, 163000, China
Research Site
Foshan, 528000, China
Research Site
Guangzhou, 510080, China
Research Site
Guangzhou, 510180, China
Research Site
Guangzhou, 510630, China
Research Site
Guiyang, 550004, China
Research Site
Haikou, 570311, China
Research Site
Hangzhou, 310009, China
Research Site
Hohhot, 010017, China
Research Site
Hohhot, 10050, China
Research Site
Jinan, 250001, China
Research Site
Jinzhou, 121004, China
Research Site
Liuchow, 545006, China
Research Site
Nanchang, 330006, China
Research Site
Nanjing, 210029, China
Research Site
Nantong, 226001, China
Research Site
Ningbo, 315010, China
Research Site
Shanghai, 200080, China
Research Site
Shanghai, 200090, China
Research Site
Shanghai, CN-200120, China
Research Site
Shenyang, 110016, China
Research Site
Taiyuan, 030001, China
Research Site
Tangshan, 063001, China
Research Site
Tianjin, 300060, China
Research Site
Tianjin, 300121, China
Research Site
Wenzhou, 325000, China
Research Site
Wuhan, 430022, China
Research Site
Wuhan, 430033, China
Research Site
Wuhan, 430060, China
Research Site
Wuxi, 214002, China
Research Site
Xi'an, 710061, China
Research Site
Xiamen, 361004, China
Research Site
Xining, 810001, China
Research Site
Xuzhou, 221006, China
Research Site
Brno, 656 91, Czechia
Research Site
Chomutov, 430 12, Czechia
Research Site
Ostrava, 703 84, Czechia
Research Site
Ostrava, 708 52, Czechia
Research Site
Pardubice, 520 03, Czechia
Research Site
Prague, 140 59, Czechia
Research Site
Ústí nad Labem, 401 13, Czechia
Research Site
Bayonne, 64100, France
Research Site
Besançon, 25030, France
Research Site
Bordeaux, 33076, France
Research Site
Bourg-en-Bresse, 01012, France
Research Site
Brest, 29609, France
Research Site
Caen, 14033, France
Research Site
Corbeil-Essonnes, 91106, France
Research Site
Dijon, 21079, France
Research Site
Le Chesnay, 78157, France
Research Site
Lille, 59037, France
Research Site
Metz, 57085, France
Research Site
Montpellier, 34295, France
Research Site
Nancy, 54035, France
Research Site
Nice, 06001, France
Research Site
Paris, 75019, France
Research Site
Paris, 75475, France
Research Site
Paris, 75571, France
Research Site
Paris, 75651, France
Research Site
Paris, 75877, France
Research Site
Rennes, 35033, France
Research Site
Rouen, 76031, France
Research Site
Saint-Herblain, 44093, France
Research Site
Saint-Priez En Jarez, 42270, France
Research Site
Strasbourg, 67098, France
Research Site
Suresnes, 92151, France
Research Site
Toulouse, 31059, France
Research Site
Altenburg, 04600, Germany
Research Site
Bad Neustadt an der Saale, 97616, Germany
Research Site
Berlin, 12351, Germany
Research Site
Erlangen, 91054, Germany
Research Site
Essen, 45147, Germany
Research Site
Hamburg, 20099, Germany
Research Site
Hamburg, 22043, Germany
Research Site
Hamburg, 22291, Germany
Research Site
Hamburg, 22763, Germany
Research Site
Hanover, 30625, Germany
Research Site
Minden, 32429, Germany
Research Site
Münster, 48149, Germany
Research Site
Hong Kong, Hong Kong
Research Site
Kowloon, Hong Kong
Research Site
Baja, 6500, Hungary
Research Site
Balassagyarmat, 2660, Hungary
Research Site
Budapest, 1083, Hungary
Research Site
Budapest, 1106, Hungary
Research Site
Budapest, 1125, Hungary
Research Site
Budapest, 1134, Hungary
Research Site
Budapest, 1204, Hungary
Research Site
Debrecen, 4043, Hungary
Research Site
Győr, 9000, Hungary
Research Site
Kistarcsa, 2143, Hungary
Research Site
Miskolc, 3526, Hungary
Research Site
Nyíregyháza, 4400, Hungary
Research Site
Pécs, 7623, Hungary
Research Site
Sopron-Balf, 9494, Hungary
Research Site
Székesfehérvár, 8000, Hungary
Research Site
Tatabánya, 2800, Hungary
Research Site
Bangalore, 560002, India
Research Site
Bangalore, 560068, India
Research Site
Bengaluru, 560076, India
Research Site
Dehradun, 248001, India
Research Site
Guntur, 522001, India
Research Site
Gūrgaon, 122001, India
Research Site
Gūrgaon, 122002, India
Research Site
Hyderabad, 500018, India
Research Site
Kanpur, 208002, India
Research Site
Kolkata, 700017, India
Research Site
Mangalore, 575002, India
Research Site
Nagpur, 420012, India
Research Site
Nagpur, 440012, India
Research Site
Nashik, 422005, India
Research Site
New Delhi, 110005, India
Research Site
New Delhi, 110026, India
Research Site
New Delhi, 110029, India
Research Site
Srikakulam, 532001, India
Research Site
Varanasi, 221004, India
Research Site
Cona, 44124, Italy
Research Site
Genova, 16128, Italy
Research Site
Genova, 16132, Italy
Research Site
Massa, 55100, Italy
Research Site
Milan, 20132, Italy
Research Site
Modena, 41100, Italy
Research Site
Negrar, 37024, Italy
Research Site
Pavia, 27100, Italy
Research Site
Perugia, 06132, Italy
Research Site
Pietra Ligure, 17027, Italy
Research Site
Pisa, 56100, Italy
Research Site
Roma, 00144, Italy
Research Site
Roma, 00152, Italy
Research Site
Roma, 00161, Italy
Research Site
Siena, 53100, Italy
Research Site
Varese, 21100, Italy
Research Site
Verona, 37126, Italy
Research Site
Vicenza, 36100, Italy
Research Site
Vizzolo Predabissi, 20070, Italy
Research Site
Culiacán, 80230, Mexico
Research Site
D.F, 14269, Mexico
Research Site
Durango, 34217, Mexico
Research Site
Guadalajara, 44280, Mexico
Research Site
Mexico City, 07760, Mexico
Research Site
Mexico City, 6726, Mexico
Research Site
México, 01090, Mexico
Research Site
México, 03103, Mexico
Research Site
Monterrey, 64460, Mexico
Research Site
Tijuana, 22321, Mexico
Research Site
Bellavista, CALLAO 2, Peru
Research Site
Callao, CALLAO 02, Peru
Research Site
Lima, LIMA 01, Peru
Research Site
Lima, LIMA 13, Peru
Research Site
Lima, LIMA 1, Peru
Research Site
Lima, LIMA 31, Peru
Research Site
Lima, Lima-1, Peru
Research Site
Trujillo, 130101, Peru
Research Site
Urb. El Chipe, 20007, Peru
Research Site
Bialystok, 15-276, Poland
Research Site
Chełm, 22-100, Poland
Research Site
Działdowo, 13-200, Poland
Research Site
Gdansk, 80-803, Poland
Research Site
Gdansk, 80-952, Poland
Research Site
Gmina Końskie, 26-200, Poland
Research Site
Gmina Świebodzin, 66-200, Poland
Research Site
Grodzisk Mazowiecki, 05-825, Poland
Research Site
Gryfice, 72-300, Poland
Research Site
Katowice, 40-635, Poland
Research Site
Krakow, 31-826, Poland
Research Site
Lodz, 90-153, Poland
Research Site
Lodz, 93-113, Poland
Research Site
Lublin, 20-954, Poland
Research Site
Olsztyn, 10-082, Poland
Research Site
Olsztyn, 10-560, Poland
Research Site
Ostrołęka, 07-410, Poland
Research Site
Rybnik, 44-200, Poland
Research Site
Sandomierz, 27-600, Poland
Research Site
Skarżysko-Kamienna, 26-110, Poland
Research Site
Warsaw, 02-957, Poland
Research Site
Warsaw, 03-242, Poland
Research Site
Zielona Góra, 65-046, Poland
Research Site
Bucharest, 011461, Romania
Research Site
Bucharest, 020125, Romania
Research Site
Bucharest, 050098, Romania
Research Site
Iași, 700309, Romania
Research Site
Oradea, 410169, Romania
Research Site
Sibiu, 550166, Romania
Research Site
Târgu Mureş, 540136, Romania
Research Site
Timișoara, 300736, Romania
Research Site
Chelyabinsk, 454106, Russia
Research Site
Izhevsk, 426063, Russia
Research Site
Kazan', 420012, Russia
Research Site
Kazan', 420101, Russia
Research Site
Kemerovo, 650002, Russia
Research Site
Moscow, 109004, Russia
Research Site
Moscow, 115516, Russia
Research Site
Moscow, 117292, Russia
Research Site
Moscow, 117997, Russia
Research Site
Moscow, 121374, Russia
Research Site
Moscow, 123367, Russia
Research Site
Nizhny Novgorod, 603005, Russia
Research Site
Nizhny Novgorod, 603018, Russia
Research Site
Novosibirsk, 630003, Russia
Research Site
Novosibirsk, 630051, Russia
Research Site
Ryazan, 390039, Russia
Research Site
Saint Petersburg, 192242, Russia
Research Site
Saint Petersburg, 194354, Russia
Research Site
Saint Petersburg, 196247, Russia
Research Site
Saint Petersburg, 196601, Russia
Research Site
Samara, 443095, Russia
Research Site
Samara, 443096, Russia
Research Site
Saratov, 410030, Russia
Research Site
Sochi, 354057, Russia
Research Site
Tomsk, 634063, Russia
Research Site
Ufa, 450071, Russia
Research Site
Voronezh, 394066, Russia
Research Site
Yaroslavl, 150030, Russia
Research Site
Yekaterinburg, 620102, Russia
Research Site
Jeddah, 21423, Saudi Arabia
Research Site
Riyadh, 11426, Saudi Arabia
Research Site
Riyadh, 11525, Saudi Arabia
Research Site
Riyadh, 12372, Saudi Arabia
Research Site
Dolný Kubín, 02614, Slovakia
Research Site
Levoča, 054 01, Slovakia
Research Site
Liptovský Mikuláš, 031 23, Slovakia
Research Site
Martin, 03659, Slovakia
Research Site
Nitra, 949 01, Slovakia
Research Site
Rimavská Sobota, 97912, Slovakia
Research Site
Skalica, 909 82, Slovakia
Research Site
Spišská Nová Ves, 052 01, Slovakia
Research Site
Trenčín, 81171, Slovakia
Research Site
Trnava, 91701, Slovakia
Research Site
Žiar nad Hronom, 96537, Slovakia
Research Site
Anyang-si, 14068, South Korea
Research Site
Busan, 49201, South Korea
Research Site
Busan, 49241, South Korea
Research Site
Cheongju-si, 28644, South Korea
Research Site
Daegu, 42415, South Korea
Research Site
Daegu, 42601, South Korea
Research Site
Daegu, 700-721, South Korea
Research Site
Daejeon, 35233, South Korea
Research Site
Goyang-si, 411-706, South Korea
Research Site
Gwangju, 61469, South Korea
Research Site
Incheon, 400-711, South Korea
Research Site
Jeju-do, 63241, South Korea
Research Site
Seongnam-si, 13620, South Korea
Research Site
Seoul, 01830, South Korea
Research Site
Seoul, 02053, South Korea
Research Site
Seoul, 02447, South Korea
Research Site
Seoul, 04401, South Korea
Research Site
Albacete, 02006, Spain
Research Site
Alicante, 03010, Spain
Research Site
Badalona(Barcelona), 08916, Spain
Research Site
Barcelona, 08003, Spain
Research Site
Barcelona, 08025, Spain
Research Site
Barcelona, 08035, Spain
Research Site
Girona, 17007, Spain
Research Site
Lleida, 25198, Spain
Research Site
Madrid, 28006, Spain
Research Site
Madrid, 28034, Spain
Research Site
Seville, 41009, Spain
Research Site
Seville, 41013, Spain
Research Site
Valencia, 46009, Spain
Research Site
Valladolid, 47005, Spain
Research Site
Zaragoza, 50009, Spain
Research Site
Gothenburg, 413 45, Sweden
Research Site
Linköping, 581 85, Sweden
Research Site
Lund, 221 85, Sweden
Research Site
Malmo, 205 02, Sweden
Research Site
Östersund, 831 83, Sweden
Research Site
Skövde, 541 85, Sweden
Research Site
Solna, 171 76, Sweden
Research Site
Stockholm, 118 83, Sweden
Research Site
Stockholm, 182 88, Sweden
Research Site
Uppsala, 751 85, Sweden
Research Site
Changhua, 500, Taiwan
Research Site
Kaohsiung City, 80756, Taiwan
Research Site
Kaohsiung City, 83301, Taiwan
Research Site
Keelung, 20448, Taiwan
Research Site
New Taipei City, 23561, Taiwan
Research Site
New Taipei City, 237, Taiwan
Research Site
Taichung, 40447, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Taichung, 437, Taiwan
Research Site
Tainan, 704, Taiwan
Research Site
Tainan, 710, Taiwan
Research Site
Taipei, 10002, Taiwan
Research Site
Taipei, 10449, Taiwan
Research Site
Taipei, 11101, Taiwan
Research Site
Taipei, 116, Taiwan
Research Site
Taoyuan Hsien, 33305, Taiwan
Research Site
Bangkok, 10220, Thailand
Research Site
Bangkok, 10300, Thailand
Research Site
Bangkok, 10330, Thailand
Research Site
Bangkok, 10400, Thailand
Research Site
Bangkok, 10600, Thailand
Research Site
Bangkok, 10700, Thailand
Research Site
Chon Buri, 20000, Thailand
Research Site
Hat Yai, 90110, Thailand
Research Site
Khlong Luang, 12120, Thailand
Research Site
Khon Kaen, 40002, Thailand
Research Site
Lampang, 52000, Thailand
Research Site
Muang, 57000, Thailand
Research Site
Nakhonpathom, 73000, Thailand
Research Site
Prachinburi, 25000, Thailand
Research Site
Rajthevi, 10400, Thailand
Research Site
Ratchaburi, 70000, Thailand
Research Site
Ubonratchathani, 34000, Thailand
Research Site
Chernivtsі, 58001, Ukraine
Research Site
Ivano-Frankivsk, 76008, Ukraine
Research Site
Ivano-Frankivsk, 76018, Ukraine
Research Site
Kharkiv Region, 61018, Ukraine
Research Site
Kharkiv Region, 61176, Ukraine
Research Site
Kherson, 73000, Ukraine
Research Site
Kyiv, 03129, Ukraine
Research Site
Lutsk, 43024, Ukraine
Research Site
Lviv, 79013, Ukraine
Research Site
Poltava, 36038, Ukraine
Research Site
Ternopil, 46027, Ukraine
Research Site
Vinnytsia, 21005, Ukraine
Research Site
Zaporizhzhia, 69068, Ukraine
Research Site
Zaporizhzhia, 69600, Ukraine
Research Site
Hanoi, 10000, Vietnam
Research Site
Hà Nội, 10000, Vietnam
Research Site
Ho Chi Minh City, 70000, Vietnam
Research Site
Đông Nãi, 81000, Vietnam
Related Publications (9)
Tank A, Johnston SC, Jain R, Amarenco P, Mellstrom C, Rikner K, Denison H, Ladenvall P, Knutsson M, Himmelmann A, Evans SR, James S, Molina CA, Wang Y, Ouwens M. Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial. BMJ Neurol Open. 2023 Aug 24;5(2):e000478. doi: 10.1136/bmjno-2023-000478. eCollection 2023.
PMID: 37637218DERIVEDJohnston SC, Amarenco P, Aunes M, Denison H, Evans SR, Himmelmann A, Jahreskog M, James S, Knutsson M, Ladenvall P, Molina CA, Nylander S, Rother J, Wang Y; THALES Investigators. Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke. 2021 Nov;52(11):3482-3489. doi: 10.1161/STROKEAHA.121.035555. Epub 2021 Sep 3.
PMID: 34477459DERIVEDWang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Birve F, Ladenvall P, Molina CA, Johnston SC; THALES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA Neurol. 2021 Sep 1;78(9):1091-1098. doi: 10.1001/jamaneurol.2021.2440.
PMID: 34244703DERIVEDYaghi S, de Havenon A, Rostanski S, Kvernland A, Mac Grory B, Furie KL, Kim AS, Easton JD, Johnston SC, Henninger N. Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. Stroke. 2021 Jul;52(7):2414-2417. doi: 10.1161/STROKEAHA.121.034089. Epub 2021 May 4.
PMID: 33940954DERIVEDAmarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC; THALES Steering Committee and Investigators*. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020 Dec;51(12):3504-3513. doi: 10.1161/STROKEAHA.120.032239. Epub 2020 Nov 16.
PMID: 33198608DERIVEDAmarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC; THALES Steering Committee and Investigators. Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. JAMA Neurol. 2020 Nov 7;78(2):1-9. doi: 10.1001/jamaneurol.2020.4396. Online ahead of print.
PMID: 33159526DERIVEDJohnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-217. doi: 10.1056/NEJMoa1916870.
PMID: 32668111DERIVEDJohnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators. The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. Int J Stroke. 2019 Oct;14(7):745-751. doi: 10.1177/1747493019830307. Epub 2019 Feb 12.
PMID: 30747613DERIVEDWong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC; SOCRATES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18.
PMID: 29915123DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Clinical Lead
- Organization
- Study Information Center
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2017
First Posted
November 28, 2017
Study Start
January 22, 2018
Primary Completion
December 13, 2019
Study Completion
December 13, 2019
Last Updated
December 22, 2020
Results First Posted
December 22, 2020
Record last verified: 2020-12